Rivoceranib
- Generic Name
- Rivoceranib
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
- Conditions
- Recurrent Cervical CancerPersistent Cervical CancerStage IVB Cervical Cancer
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-10-01
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT04974944
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04948125
- Locations
- 🇨🇳
Henan cancer hospital/The affiliated Cancer Hospital of ZhengZhou university, Henan, China
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 78
- Registration Number
- NCT04930315
- Locations
- 🇨🇳
the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Wuhan University
- Target Recruit Count
- 88
- Registration Number
- NCT04878107
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Peking University
- Target Recruit Count
- 41
- Registration Number
- NCT04863430
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
- Conditions
- Hepatocellular Carcinoma Resectable
- Interventions
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2021-04-20
- Target Recruit Count
- 15
- Registration Number
- NCT04850040
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Beijing Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04832204
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China
Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT04824352
- Locations
- 🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
- Conditions
- Metastatic Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Zhou Fuxiang
- Target Recruit Count
- 35
- Registration Number
- NCT04781686
- Locations
- 🇨🇳
Zhongnan Hopital of Wuhan University, Wuhan, Hubei, China
Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 34
- Registration Number
- NCT04724226
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.